AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04557020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: neoadjuvant chemotherapy: 80mg/m2 in day 1, and repeats every 3 weeks for 3 cycles. Concurrent chemoradiotherapy: Cisplatin 100mg/m2 in day 1, 22, and 43 during IMRT
Study NCT04248725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-TIPS
Description: Chronic pain self-management strategies for employed individuals with physical disabilities
Study NCT04453774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Covidfree@home
Description: Mobile phone, Covidfree@home app, thermometer, pulse oximeter, smart watch
Study NCT04094311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTL019
Description: A single intravenous (i.v.) infusion of CAR-positive viable T cells.
Study NCT03392467 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNEUMOSTEM
Description: human umbilical cord blood-derived mesenchymal stem cells
Study NCT03392467 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline
Study NCT04557020 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: neoadjuvant chemotherapy: 80mg/m2 in day 1, and repeats every 3 weeks for 3 cycles. Concurrent chemoradiotherapy: Cisplatin 100mg/m2 in day 1, 22, and 43 during IMRT
Study NCT04557020 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: 70Gy to GTV, 60Gy to CTV1 and 54Gy to CTV2 in 32 to 33 fractions
Study NCT04557020 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: 70Gy to GTV, 60Gy to CTV1 and 54Gy to CTV2 in 32 to 33 fractions
Study NCT01568970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Return-to-work Rehabilitation + Follow up
Description: 3 1/2 weeks of Return-to-work rehabilitation followed by 6 months of Return-to-work follow-up
Study NCT01568970 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Return-to-work rehabilitation
Description: 3 1/2 weeks of Return-to-work rehabilitation followed by standard follow-up
Study NCT01104467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmoteplase
Description: 1 bolus injection of desmoteplase 70 µg/kg intravenous (IV)
Study NCT01104467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmoteplase
Description: 1 bolus injection of desmoteplase 90 µg/kg (IV)
Study NCT00255008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 24 weeks
Study NCT01104467 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 bolus injection of placebo IV
Study NCT01604135 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal Collagen Crosslinking
Description: Keratoconic corneas that show significant progression as specified in the inclusion criteria section will receive one single treatment with CXL if randomized to the treatment arm. A treatment protocol based on 30 minutes dropping with riboflavin/dextran solution and 10 minutes UV-illumination treatment will be used.
Study NCT03233711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT00422240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene/Benzoyl Peroxide
Description: Adapalene 0.1 % \[weight by weight (W/W)\]/benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening for 12 Weeks.
Study NCT00422240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene Gel, 0.1%
Description: 0.1% of adapalene gel topically daily in the evening for 12 Weeks.
Study NCT00422240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl Peroxide Gel 2.5%
Description: 2.5% of benzoyl peroxide gel topically daily in the evening for 12 Weeks.
Study NCT03233711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03233711 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03233711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Undergo colonoscopy
Study NCT03233711 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Colonoscopy
Description: Undergo colonoscopy
Study NCT03233711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT02697864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Study NCT01445262 — intervention group
Intervention type: DRUG
Intervention: Levocetirizine
Study NCT01523171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503
Description: Pharmaceutical form:capsule~Route of administration: oral
Study NCT02705469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZEN003694
Study NCT01819831 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: proton radiation
Description: proton radiation: 2 GyE/Day to isocenter, one treatment per day, 5 days per week for 25 treatments (=50 GyE to isocenter/25 fractions)
Study NCT01819831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery (wide local excision; limb preservation surgery)
Description: In areas with ample soft tissue that can be removed without compromising future function or wound closure, wide margins is the goal of treatment; associated rates of local failure are low in such instances. Margins will be determined by the surgeon; the goal is to achieve at least a 2 mm negative margin resection. However, smaller margins can be acceptable if it allows for limb-sparing surgery with conserved functional outcomes. Every effort will be made to have limb preservation surgery unless there is documented evidence of tumor progression during or after the course of radiation that would require amputation for an appropriate margin resection.
Study NCT01560793 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX161 [STF2.HA5 H5N1]
Description: dose escalating, 2 intramuscular doses given 21 days apart
Study NCT00970567 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Different insulin therapy at different time points
Description: different insulin therapy after positive blood ketones
Study NCT01749137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setmelanotide
Description: Daily subcutaneous infusion
Study NCT01749137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily subcutaneous infusion
Study NCT02598544 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: adipose tissue sampling
Description: adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination
Study NCT02826902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol and remifentanil
Description: Anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil
Study NCT02826902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desflurane and remifentanil
Description: Anesthesia is induced and maintained with desflurane and remifentanil
Study NCT03791723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan
Description: After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 50 mg LCZ696 for 2-4 weeks, then uptitrated to 100 mg bid for 2-4 weeks, and thereafter, uptitrated to 200 mg bid or tolerable maximum dose ≥6 months.
Study NCT03558854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
Study NCT03558854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Patients will be randomized to take one pill of either acetylsalicylic acid or placebo once daily for 4 weeks
Study NCT01559597 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid vaccine
Description: Two doses of tetanus toxoid vaccine separated at least 4 weeks. One arm receives the vaccine kept in cold chain and the other arm receives the vaccine kept in CTC
Study NCT01559597 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus toxoid vaccine
Description: Two doses of tetanus toxoid vaccine separated at least 4 weeks. One arm receives the vaccine kept in cold chain and the other arm receives the vaccine kept in CTC
Study NCT03233711 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT03233711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Rectal Examination
Description: Undergo digital rectal examination
Study NCT03700775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Telemonitoring
Description: Using the telemedicine kit, participants will record a daily health session including 2 BP measurements obtained one minute apart. Participants are encouraged to record a health session every day, with a minimum of 5 days per week. Participants are also encouraged to equally divide health session recordings between the mornings and evenings. Every 2 weeks BP measurements will be assessed. If less than 75% of measurements are at goal \<130/80 mmHg, the central Telehealth pharmacist will designate drug-therapy intensification according to an evidence-based treatment algorithm that is physician approved. Regardless of BP control, participants will be contacted by their nurse coordinator every 2 weeks. During all telephone visits nurse coordinators emphasize healthy lifestyle habits. Safety protocols are in place for dangerously high or low BP recordings.
Study NCT01927237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HLR
Study NCT03233711 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Digital Rectal Examination
Description: Undergo digital rectal examination
Study NCT03233711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High Resolution Anoscopy
Description: Undergo anoscopy
Study NCT01927237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHR
Study NCT05166824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TempSure
Description: Radiofrequency platform
Study NCT03233711 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: High Resolution Anoscopy
Description: Undergo anoscopy
Study NCT00422240 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gel Vehicle
Description: Participants were treated with gel vehicle topically daily in the evening for 12 Weeks.
Study NCT01197794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: AZD1981 twice daily
Study NCT05166824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scalpel
Description: Cold knife
Study NCT05166824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bovie
Description: Electrosurgery and electrocautery platform
Study NCT05166824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pelleve
Description: Radiofrequency platform
Study NCT00164775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipramine
Description: 25mg nocte for first 2 weeks then 50 mg nocte for 10 weeks
Study NCT00164775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tab nocte for first 2 weeks then 2 tabs for 10 weeks
Study NCT04533581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME-401
Description: In the first 2 cycles (1 cycle is 28 days), subjects will be administered 60 mg of ME-401 orally once a day on a continuous schedule (CS). After that, subjects will be administered 60 mg of ME-401 orally once a day for the first 7 days, followed by rest for 21 days on an intermittent schedule (IS).
Study NCT04077827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Patients will be divided into 2 groups. The TIVA group (N = 23) will be administrated intravenous anesthesia (propofol-remifentanil), while to the DES group (N = 23) volatile anesthetics (desflurane-remifentanil)
Study NCT00724022 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Basiliximab, Tacrolimus, MMF, Prednisolon
Description: Control group. Therapy with Prednisolon.
Study NCT00724022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab, Tacrolimus, MMF
Description: No Prednisolon after 7 days
Study NCT00724022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus, MMF, rATG
Description: Induction therapy: rATG instead of Basiliximab. No Prednisolon.
Study NCT01095445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)
Description: Dosage Form: Pegetron - powder for solution; Rebetol - capsules Strength: Pegetron Redipen - 120 mcg per pen; Rebetol - 200 mg Route of Administration: Pegetron - subcutaneous; Rebetol - oral
Study NCT04397107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Patients were received low dose recombinant human Interleukin-2
Study NCT03947372 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Appendectomy
Description: removal of acutely inflamed appendix
Study NCT03947372 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Appendectomy
Description: removal of acutely inflamed appendix
Study NCT03506282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Running while listening to a traffic audio track
Description: While running three 2-minute sets at different velocities (6, 8 and 10 km/h, respectively) on a sensorized treadmill, each participant will be exposed via earphones to an audio track resembling average outdoor conditions (70 dB).
Study NCT03506282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Running with music at moderate volume
Description: While running three 2-minute sets at different velocities (6, 8 and 10 km/h, respectively) on a sensorized treadmill, each participant will be provided the same music track (We take care of our own, by Bruce Springsteen from the Wrecking Ball album, 2012). The music track will be given at a moderate volume (80 dB).
Study NCT03506282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Running with music at moderate-to-high volume
Description: While running three 2-minute sets at different velocities (6, 8 and 10 km/h, respectively) on a sensorized treadmill, each participant will be provided the same music track (We take care of our own, by Bruce Springsteen from the Wrecking Ball album, 2012). The music track will be given at a moderate-to-high volume (85 dB).
Study NCT01806298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saizen® solution for injection (referred as Saizen®)
Description: Saizen® solution for injection will be administered subcutaneously daily for 39 weeks according to locally approved product labeling for the currently marketed formulation of Saizen®.
Study NCT06485765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet planning
Description: Healthy eating planning
Study NCT00669227 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: autologous stem cells
Description: intracoronary administration at the same day of cell aspiration using the stop flow technique
Study NCT00669227 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo suspension
Description: intracoronary administration at the same day as cell aspiration
Study NCT02418598 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Cohort1
Description: AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 3x10\^11 vg/subject.
Study NCT02418598 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Cohort2
Description: AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 9x10\^11 vg/subject.
Study NCT01197794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: AZD1981 once daily
Study NCT01694472 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-A4 TCR Gene-Modified T Cells
Description: The study consists of a 2-dose escalation scheme, and the patient receives twice in each dose. The starting dose is 1-3 x 10\^9 cells of each TCR gene-modified cells and the second one is 3-8 x 10\^9 cells of each TCR gene-modified cells. Two weeks after the first infusion the patient receives the same dose again, followed by infusions of IL-2 for 5 days. Thereafter, the patient receives peptide vaccinations on days 21 and 28.
Study NCT03791723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: After catheter ablation,during a single blind, run-in period, participants received placebo. Then started with 40 mg Valsartan daily (qd) for 2-4 weeks, then were uptitrated to 80mg qd or tolerable maximum dose ≥6 months.
Study NCT00661011 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lobectomy followed by concomitant mediastinal chemoradiotherapy
Description: Lobectomy Radiotherapy 66 Gy in 2 Gy/ fraction, 5 fractions/wk Chemotherapy Cisplatin 60 mg/m² on days 1 and 22 and Vinorelbine 15 mg/m² on days 1, 8, 22 and 29
Study NCT01912365 — intervention group
Intervention type: PROCEDURE
Intervention: Above Elbow Cast
Study NCT04197050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril / Valsartan Oral Tablet
Description: After recruiting participants and collecting the baseline information, sacubitril/valsartan group will receive sacubitril/valsartan and optimal pharmaceutical treatment (OPT). The control group will receive valsartan and OPT. A CMR scan and a post-processed imaging procedure will later be carried on in order to detect the cardiac impairment.
Study NCT04587063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear Appeals
Description: Email
Study NCT04587063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message about Future Healthcare Costs
Description: Email
Study NCT04587063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endorsement from a Doctor
Description: Email
Study NCT04587063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comparison Table
Description: Email
Study NCT04587063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Highlighting Cost Savings and Convenience
Description: Email
Study NCT01197794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match AZD1981
Study NCT04587063 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Highlighting Cost Savings and Convenience
Description: Email
Study NCT00975403 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dead space breathing
Description: Chemical loading by adding a deadspace (600ml) to the breathing circuit during a single cycle exercise test
Study NCT00975403 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Room air breathing
Description: Sham comparator (vs deadspace) during a single cycle exercise test will entail breathing room air on the same circuit without the rebreathe valves
Study NCT03553953 — intervention group
Intervention type: DEVICE
Intervention: BIS device
Description: Recording data from BIS device from patients who undergo elective surgery under general anesthesia
Study NCT04237337 — intervention group
Intervention type: OTHER
Intervention: Exposure to MS drugs
Description: Exposure in ICSRs to MS drugs (dichotomous, exposed/not exposed), for each individual MS drug
Study NCT04447339 — intervention group
Intervention type: PROCEDURE
Intervention: Nipple Sparing Mastectomy
Description: Prophylactic open NSM procedures
Study NCT00760851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: probiotic strain Bb-12
Description: 10\^9 CFU Bb-12 per 4 oz yogurt
Study NCT00760851 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no Bb-12
Description: yogurt identical to intervention yogurt, only without Bb-12 added.
Study NCT04307576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omitted Doxorubicin
Description: Omission of IV Doxorubicin
Study NCT04307576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omitted Vincristine+Dexamethasone pulses
Description: Omission of Vincristine+Dexamethasone pulses
Study NCT01912365 — intervention group
Intervention type: PROCEDURE
Intervention: Long Arm Splint
Study NCT01861964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Maltodextrin)
Description: Maltodextrin 505mg/capsule 8 capsules/day (4 with breakfast and 4 with dinner meal)
Study NCT01861964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xylooligosarcharide 1.4g
Description: 8 capsules (512 mg/capsule) 4 with breakfast and 4 with dinner meal
Study NCT01861964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xylooligosarcharide 2.8g
Description: 8 capsules (520 mg/capsule) to be taken in the morning and in the evening
Study NCT00980057 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive CRT (aCRT)
Description: Adaptive CRT (aCRT) is an algorithm, which provides ambulatory adjustment of pacing configuration (LV-only or BiV) and AV and VV delays based on periodic automatic evaluation of electrical conduction to optimize cardiac function